Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ClearPoint Neuro, Inc.CLPT · Entity 2367 | Director | May 21, 2026 | May 26, 2026 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director · CHIEF EXECUTIVE OFFICER | August 04, 2026 | August 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ClearPoint Neuro, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,935 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Sale · Disposed 16,000 · Balance 46,935 F1: Represents a weighted average sales price per share. The shares were sold at prices ranging from $11.57 to $11.65. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,820 |
Reported balance
After 2026-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-21 · Grant · Acquired 12,820 · Balance 12,820 F2: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F3: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a weighted average sales price per share. The shares were sold at prices ranging from $11.57 to $11.65. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F2: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock.
F3: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2027 annual meeting of stockholders.
PTC THERAPEUTICS, INC.
Report date August 04, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 383,868 |
Reported balance
After 2026-08-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-04 · Sale · Disposed 10,292 · Balance 383,868 F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of the 25,000 RSUs from an August 1, 2025 grant of 75,000 RSUs. F2: Includes 162 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of the 25,000 RSUs from an August 1, 2025 grant of 75,000 RSUs.
F2: Includes 162 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 11, 2023 Filed Jan 12, 2023 21:36 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,244 | $44.36 | $99,542.94 |
DisclosureSEC source: 0001415889-23-000879 · form4-01122023_090129.xml · nonDerivative · entry 2 Klein Matthew B. · CIK 0001808968 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,856 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 15,250 RSUs from January 7, 2022 grants of a total of 41,000 RSUs. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:36 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,273 | $42.93 | $97,586.48 |
DisclosureSEC source: 0001415889-23-000879 · form4-01122023_090129.xml · nonDerivative · entry 1 Klein Matthew B. · CIK 0001808968 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,100 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 15,250 RSUs from January 7, 2022 grants of a total of 41,000 RSUs. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 23:13 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 731 | $41.66 | $30,450.68 |
DisclosureSEC source: 0001415889-23-000836 · form4-01112023_110124.xml · nonDerivative · entry 1 Klein Matthew B. · CIK 0001808968 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,373 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,250 RSUs from a January 6, 2021 grant of 9,000 RSUs. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001415889-23-000689 · form4-01092023_090149.xml · derivative · entry 2 Klein Matthew B. · CIK 0001808968 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-01-04 F3 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000689 · form4-01092023_090149.xml · nonDerivative · entry 1 Klein Matthew B. · CIK 0001808968 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,104 F1 · shares: Restricted stock units granted on January 5, 2023 that vest in four equal installments over four years, commencing on January 5, 2024. F2 · balance_after: Includes 263 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2022 and 277 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2022. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:27 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 6,179 | $0.00 Strike: $9.71 | $0.00 |
DisclosureSEC source: 0001420506-22-001135 · doc4_1012.xml · derivative · entry 2 Klein Matthew B. · CIK 0001808968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,179 Underlying: Common Stock · 6,179 shares Expires 2032-05-25 F2 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2023 annual meeting of stockholders. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:27 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 9,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001420506-22-001135 · doc4_1012.xml · nonDerivative · entry 1 Klein Matthew B. · CIK 0001808968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,272 F1 · price: The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2023 annual meeting of stockholders. Read SEC document |
| April 19, 2022 Filed Apr 21, 2022 20:03 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 897 | $42.52 | $38,135.96 |
DisclosureSEC source: 0001415889-22-004211 · form4-04212022_010449.xml · nonDerivative · entry 1 Klein Matthew B. · CIK 0001808968 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,564 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,500 RSUs from a April 16, 2020 grant of 10,000 RSUs. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:18 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001179110-22-000397 · edgar.xml · derivative · entry 5 Klein Matthew B. · CIK 0001808968 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-06 F6 · derivative.exercise_date: This option was granted on January 7, 2022 and vests in two equal installments over two years, commencing on January 7, 2023. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:18 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001179110-22-000397 · edgar.xml · derivative · entry 4 Klein Matthew B. · CIK 0001808968 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2032-01-06 F5 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:18 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000397 · edgar.xml · nonDerivative · entry 3 Klein Matthew B. · CIK 0001808968 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,461 F4 · shares: Restricted stock units granted on January 7, 2022 that vest in two equal installments over two years, commencing on January 7, 2023. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:18 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000397 · edgar.xml · nonDerivative · entry 2 Klein Matthew B. · CIK 0001808968 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,461 F3 · shares: Restricted stock units granted on January 7, 2022 that vest in four equal installments over four years, commencing on January 7, 2023. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:18 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 775 | $38.53 | $29,856.88 |
DisclosureSEC source: 0001179110-22-000397 · edgar.xml · nonDerivative · entry 1 Klein Matthew B. · CIK 0001808968 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,461 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,250 RSUs from a January 6, 2021 grant of 9,000 RSUs. F2 · balance_after: Includes 203 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2021 and 224 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2021. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 12:40 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 6,006 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001171520-21-000266 · ownership.xml · derivative · entry 2 Klein Matthew B. · CIK 0001808968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,006 Underlying: Common Stock · 6,006 shares Expires 2031-06-25 F2 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 12:40 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 3,003 | $0.00 | $0.00 |
DisclosureSEC source: 0001171520-21-000266 · ownership.xml · nonDerivative · entry 1 Klein Matthew B. · CIK 0001808968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,003 F1 · security: The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders. F1 · shares: The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders. Read SEC document |
| April 20, 2021 Filed Apr 21, 2021 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 197 | $47.92 | $9,440.04 |
DisclosureSEC source: 0001179110-21-004535 · edgar.xml · nonDerivative · entry 3 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,809 F2 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 10, 2021. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.68 to $48.17 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 20, 2021 Filed Apr 21, 2021 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,444 | $46.58 | $67,264.41 |
DisclosureSEC source: 0001179110-21-004535 · edgar.xml · nonDerivative · entry 2 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,006 F2 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 10, 2021. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $46.24 to $47.06 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 859 | $48.17 | $41,376.31 |
DisclosureSEC source: 0001179110-21-004535 · edgar.xml · nonDerivative · entry 1 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,450 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,500 RSUs from a April 16, 2020 grant of 10,000 RSUs. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,300 | $38.98 Strike: $38.98 | $167,614.00 |
DisclosureSEC source: 0001179110-21-000733 · edgar.xml · derivative · entry 3 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,314 Underlying: Common Stock · 4,300 shares Expires 2029-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 2, 2020. F3 · derivative.exercise_date: This option was granted on October 25, 2019, and vests over four years, with 25% of the shares underlying the option vesting on October 28, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on January 28, 2021. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,300 | $69.09 | $297,078.40 |
DisclosureSEC source: 0001179110-21-000733 · edgar.xml · nonDerivative · entry 2 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,309 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 2, 2020. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.98 to $69.28 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 4,300 | $38.98 | $167,614.00 |
DisclosureSEC source: 0001179110-21-000733 · edgar.xml · nonDerivative · entry 1 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 2, 2020. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:17 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,500 | $38.98 Strike: $38.98 | $214,390.00 |
DisclosureSEC source: 0001179110-21-000539 · edgar.xml · derivative · entry 4 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,614 Underlying: Common Stock · 5,500 shares Expires 2029-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 2, 2020. F4 · derivative.exercise_date: This option was granted on October 25, 2019, and vests over four years, with 25% of the shares underlying the option vesting on October 28, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on January 28, 2021. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:17 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,500 | $70.32 | $105,486.00 |
DisclosureSEC source: 0001179110-21-000539 · edgar.xml · nonDerivative · entry 3 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,309 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 2, 2020. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $70.00 to $70.61 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:17 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,000 | $69.48 | $277,924.00 |
DisclosureSEC source: 0001179110-21-000539 · edgar.xml · nonDerivative · entry 2 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,809 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 2, 2020. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.98 to $69.93 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:17 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 5,500 | $38.98 | $214,390.00 |
DisclosureSEC source: 0001179110-21-000539 · edgar.xml · nonDerivative · entry 1 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 2, 2020. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:12 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,886 | $38.98 Strike: $39.98 | $151,476.28 |
DisclosureSEC source: 0001179110-21-000467 · edgar.xml · derivative · entry 5 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,114 Underlying: Common Stock · 3,886 shares Expires 2029-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 2, 2020. F5 · derivative.exercise_date: This option was granted on October 25, 2019, and vests over four years, with 25% of the shares underlying the option vesting on October 28, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on January 28, 2021. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:12 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,886 | $68.98 | $268,056.28 |
DisclosureSEC source: 0001179110-21-000467 · edgar.xml · nonDerivative · entry 3 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,309 F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 2, 2020. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:12 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 3,886 | $38.98 | $151,476.28 |
DisclosureSEC source: 0001179110-21-000467 · edgar.xml · nonDerivative · entry 2 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 2, 2020. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:12 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $66.49 | $0.00 |
DisclosureSEC source: 0001179110-21-000467 · edgar.xml · derivative · entry 4 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2031-01-05 F4 · derivative.exercise_date: This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:12 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-000467 · edgar.xml · nonDerivative · entry 1 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,309 F1 · shares: Restricted stock units granted on January 6, 2021 that vest in four equal installments over four years, commencing on January 6, 2022. F2 · balance_after: Includes 155 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2020 and 154 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2020. Read SEC document |
| April 16, 2020 Filed Apr 17, 2020 20:28 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 50,000 | $47.49 Strike: $47.49 | $2,374,500.00 |
DisclosureSEC source: 0001070081-20-000080 · wf-form4_158715531137252.xml · derivative · entry 2 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-04-15 F2 · derivative.exercise_date: This option was granted on April 16, 2020, and vests over four years, with 25% of the shares underlying the option vesting on April 16, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on July 16, 2021. Read SEC document |
| April 16, 2020 Filed Apr 17, 2020 20:28 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-20-000080 · wf-form4_158715531137252.xml · nonDerivative · entry 1 Klein Matthew B. · CIK 0001808968 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Restricted stock units granted on April 16, 2020 that vest in four equal installments over four years, commencing on April 16, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.